Lite Strategy Inc(LITS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 30 at 4:00 PM ET (Korea 10/31 05:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1.99 | Insider Own | 1.62% | Shs Outstand | 32.4M | Perf Week | -3.45% |
| Market Cap | 0.03B | Forward P/E | - | EPS next Y | - | Insider Trans | 5.8% | Shs Float | 29.9M | Perf Month | -18.55% |
| Enterprise Value | 0.03B | PEG | - | EPS next Q | - | Inst Own | 19.68% | Short Float | 0.36% | Perf Quarter | 14.15% |
| Income | -0.07B | P/S | - | EPS this Y | - | Inst Trans | 0.01% | Short Ratio | 0.23 | Perf Half Y | -0.88% |
| Sales | 0.00B | P/B | 0.87 | EPS next 5Y | - | ROA | -233.37% | Short Interest | 0.11M | Perf YTD | -15.15% |
| Book/sh | 1.28 | P/C | 5.96 | EPS past 3/5Y | 24.47% 29.72% | ROE | -243.02% | 52W High | -50.44% ($2.26) | Perf Year | -42.56% |
| Cash/sh | 0.19 | P/FCF | - | Sales past 3/5Y | - | ROIC | -170.94% | 52W Low | 62.6% ($0.69) | Perf 3Y | -78.86% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 16.97% | Gross Margin | - | Volatility(W/M) | 5.86% 5.84% | Perf 5Y | -97.44% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.08 | Perf 10Y | -95.16% |
| Dividend Ex-Date | 2023/11/16 | Quick Ratio | 5.74 | EPS Q/Q | 6.77% | Profit Margin | - | RSI (14) | 43.93 | Recom | 2.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.74 | Sales Q/Q | - | SMA20 | -7.63% ($1.21) | Beta | 0.16 | Target Price | $22.67 |
| Payout | - | Debt/Eq | 0 | Earnings | - | SMA50 | -4.59% ($1.17) | Rel Volume | 0.57 | Prev Close | $1.17 |
| Employees | 5 | LT Debt/Eq | 0 | EPS/Sales Surpr. | - | SMA200 | 2.52% ($1.09) | Avg Volume(3M) | 0.48M | Price | $1.12 |
| IPO | 2003/12/18 | Option/Short | Yes/Yes | Trades | 392 | Volume | 270,479 | Change | -4.27% |
💎 This is the world's largest Litecoin (LTC) treasury company. Originally a biotech firm called MEI Pharma that developed cancer treatments, it pivoted its business strategy in 2025 to focus on acquiring Litecoin. It has raised $100 million in funding to aggressively purchase LTC and is headquartered in San Diego.
Over the past 1 year, roughly in the middle
50% below its 1-year high.
Traded less than usual. That is 57% of its average volume.
LITS has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -97.4%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 19.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #439 of 597 in the industry
Based on market cap of $34M.
EDSA#438 Edesa Biotech Inc $35M PER - LITS#439 Lite Strategy Inc $34M PER - 
NNVC#440 NanoViricides Inc $34M PER - 
ALDX#441 Aldeyra Therapeutics Inc $34M PER - 
IRLA#442 IRulya Therapeutics Inc $34M PER - 
FAQ
What kind of company is LITS?
LITS belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of LITS?
The market cap of LITS is approximately $34M, ranking 5,021 within its sector.
What is the 52-week high and low for LITS?
LITS has recorded a 52-week high of $2.26 and a low of $0.69.
